Assembly Biosciences
11711 North Meridian Street
Suite 310
Indianapolis
Indiana
46032
United States
Tel: 855.971.4467
Website: http://www.assemblybio.com/
Email: info@assemblybio.com
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly’s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. For more information, visit assemblybio.com.
Stock Exchange: NASDAQ
Stock Symbol: ASMB
R & D Main Facility:
Assembly Biosciences
331 Oyster Point Blvd.
South San Francisco, CA 94080
132 articles about Assembly Biosciences
-
Assembly Biosciences, Inc. provided an update on Nov. 5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection.
-
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
11/5/2020
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results and a business update for the third quarter ended September 30, 2020.
-
Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
11/5/2020
HBV field’sfirstcore inhibitor combination study to assess off-treatmentresponse has not achieved a meaningful rate ofsustained virologic response
-
Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™
11/2/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that data from its HBV core inhibitor research and development programs as well as a collaborative translational study using Assembly Bio’s sensitive HBV nucleic acid assays are featured in four abstracts accepted for presentation during The Liver Meeting Digital Experience™ (TLMdX)
-
BioSpace Movers & Shakers, Oct. 23
10/23/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Assembly Biosciences Appoints Gina Consylman to Board of Directors
10/20/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors
-
BioSpace Movers & Shakers, Oct. 16
10/16/2020
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers. -
Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact AwardDr. McHutchison Recognized for Critical Achievements in Developing Curative Treatments for Chronic Hepatitis
10/15/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary
-
Assembly Biosciences Announces October Conference Participation
10/5/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020 Panel: What are the virological and immunological gaps that need to be addressed? What biomarkers are most needed to
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020
10/2/2020
Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Company’s common stock with an exercise price of $17.29 per share, the closing price of Assembly’s common stock on October 1, 2020.
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020
9/4/2020
Assembly Biosciences, Inc. announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Company’s common stock with an exercise price of $20.14 per share, the closing price of Assembly’s common stock on September 1, 2020.
-
Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
8/28/2020
Assembly Biosciences, Inc. announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.
-
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
8/27/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 07, 2020
8/7/2020
Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock on August 3, 2020.
-
Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
8/5/2020
Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results and recent highlights for the second quarter ended June 30, 2020.
-
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
7/20/2020
BeiGene acquires exclusive development and commercialization rights to ABI-H0731, ABI-H2158, and ABI-H3733 in China
-
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
7/9/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ABI-H2158 (2158) for the treatment of patients with chronic HBV infection
-
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2020
7/2/2020
Assembly Biosciences, Inc. announced grants of stock options to ten new employees to purchase an aggregate of 112,600 shares of the Company’s common stock with an exercise price of $23.30 per share, the closing price of Assembly’s common stock on July 1, 2020.
-
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
6/25/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the initiation of a Phase 2 trial of its potent, second-generation core inhibitor, ABI-H2158 (2158). The international multi-center, randomized, placebo-controlled trial will evaluate 2158 with entecavir versus placebo with
-
Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
6/22/2020
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that preclinical data from its immuno-oncology microbiome program are currently being featured in an e-poster at the American Association for Cancer Research Virtual Annual Meeting II , June 22-24, 2020. The poster, Dis